Eosinophilic Esophagitis
Conditions
Brief summary
The current project aims to improve the care for children and adolescents with eosinophilic esophagitis in a collaborative effort involving pediatric units at Oslo Unversity Hospital and Helse Bergen, Norway. Existing and new non-invasive biomarkers will be explored systematically, aiming to reduce the number of endoscopies and time on restricted diet.
Detailed description
The overall aim of the current proposal is to improve the care for children and adolescents with EoE and reduce the need for complex elimination diets and repeated endoscopies. Our objectives are to determine whether 1. at diagnosis the following are predictive for response to food elimination: 1. history of atopy, symptoms after food intake 2. eosinophil counts in biopsies and peripheral blood 3. total IgE, specific IgE, eosinophilic granula proteins, eosinophil progenitor cells in blood 4. key cytokines (Eotaxin-3, IL-5, IL-13) 5. eosinophil derived neurotoxin/EDN in oesophageal aspirates, blood samples and feces 6. circulating microRNAs 2. at follow-up biomarkers collected by non-invasive methods can predict endoscopic and histologic healing 1. eosinophil counts in esophageal brushes and peripheral blood 2. total IgE, specific IgE, eosinophilic granula protein, eosinophil progenitor cells 3. circulating cytokines like eotaxin-3, IL-5, IL-13 4. eosinophil derived neurotoxin/EDN in esophageal brushes, blood samples and feces 5. circulating microRNAs
Interventions
OTHERBiobank sampling for new biomarkers
Using biopsies as the gold standard, the project aims towards validating non-invasive biomarkers as specified previously against biopsies.
Sponsors
Helse-Bergen HF
Oslo University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
* a diagnosis of eosinophilic esophagitis * suspected but not yet confirmed eosinophilic esophagitis
Exclusion criteria
* chronic severe conditions that preclude general anaestesia * lack of consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Active eosinophilic esophagitis (>15 eosinophils per high-power field) | 12 months | The eosinophil counts in a biopsy is used to classify active vs non-active eosinophilic esophagitis, and biomarkers are analysed using biopsy the gold standard to classify active vs inactive disease. |
Countries
Norway
Contacts
Primary ContactKetil Størdal, PhD
Backup ContactErling Tjora, PhD
Outcome results
None listed